UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest eve	nt reported)	February 25, 2008					
HENRY SCHEIN, INC.							
(Exact name of registrant as specified in its charter)							
DELAWARE	0-27078	11-3136595					
(State or other jurisdiction of incorporation)							
135 DURYEA ROAD, MELVILLE, NEW YO		11747					
(Address of principal executive offi		(Zip Code)					
Registrant's telephone number, including area code (631) 843-5500							
	APPLICABLE						
(Former name or former address, if changed since last report.)							
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):							
[] Written communications pursuant 230.425)	to Rule 425 unde	er the Securities Act (17 CFR					
[] Soliciting material pursuant to 240.14a-12)	Rule 14a-12 unde	er the Exchange Act (17 CFR					
[] Pre-commencement communications Act (17 CFR 240.14d-2(b))	pursuant to Rule	e 14d-2(b) under the Exchange					
[] Pre-commencement communications Act (17 CFR 240.13e-4(c))	pursuant to Rule	e 13e-4(c) under the Exchange					

Item 2.02. Results of Operations and Financial Condition.

On February 25, 2008, Henry Schein, Inc. issued a press release reporting the financial results for the three months and full year ended December 29, 2007. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibit 99.1 Press Release dated February 25, 2008.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HENRY SCHEIN, INC.

By: /s/ Steven Paladino
Steven Paladino
Executive Vice President and

Chief Financial Officer (principal financial and accounting officer)

February 25, 2008

EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release dated February 25, 2008.

Henry Schein, Inc. - 135 Duryea Road - Melville, New York 11747

FOR IMMEDIATE RELEASE

HENRY SCHEIN REPORTS RECORD FOURTH QUARTER AND FULL YEAR RESULTS

Fourth quarter diluted EPS from continuing operations increases 19% to \$0.83 Annual diluted EPS from continuing operations increases 27%

MELVILLE, N.Y. - February 25, 2008 - Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of healthcare products and services to office-based practitioners in the combined North American and European markets, today reported financial results for the quarter ended December 29, 2007.

Net sales for the fourth quarter of 2007 were \$1.7 billion, an increase of 16.4% compared with the fourth quarter of 2006. This increase includes 12.3% local currency growth (3.8% internally generated and 8.5% from acquisitions) and 4.1% related to foreign currency exchange. (See Exhibit A for details of sales growth.)

Income from continuing operations for the fourth quarter of 2007 was \$76.4 million or \$0.83 per diluted share, up 21.3% and 18.6%, respectively, compared with the prior-year fourth quarter.

Net income for the fourth quarter of 2007 was \$78.3 million or \$0.85 per diluted share. Results include income from discontinued operations of approximately \$1.8 million or \$0.02 per diluted share, primarily related to the gain on the sale of the Company's specialty pharmacy business.

"Our strong fourth quarter financial results close out a very solid year for Henry Schein," said Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein. "For the year our Dental, Medical, International and Technology Groups each reported double-digit sales growth and market share gains, and we are proud to have once again achieved our key long-term financial objectives for internal sales growth, operating margin expansion, EPS growth and cash flow from operations."

Dental Group sales increased 12.8% during the fourth quarter, including 11.2% growth in local currencies (9.4% internally generated and 1.8% from acquisitions) and 1.6% growth related to foreign currency exchange. Of the 11.2% local currency growth, Dental consumable merchandise sales increased 6.5% (4.6% internal growth and 1.9% acquisition growth) and Dental equipment sales and service revenues were up 21.3% (19.6% internal growth and 1.7% acquisition growth).

- more -

"Our Dental Group continues to be successful in delivering profitable growth and expanding our presence in the marketplace," commented Mr. Bergman. "Fourth quarter performance was highlighted by impressive internal growth in equipment sales and service revenues, with strong gains in both traditional equipment and high-tech products."

Medical Group sales declined 5.5% during the fourth quarter (6.0% decline in internal growth and 0.5% acquisition growth). Medical Group sales were impacted by the timing of influenza vaccine sales which, while higher in the third quarter of 2007 due to earlier shipments, were significantly lower in the fourth quarter of 2007 when compared with the fourth quarter of 2006. Excluding sales of influenza vaccine, Medical Group sales increased 3.8% for the quarter, with 3.3% internal growth. For the year influenza vaccine sales were more than 20% higher than 2006.

"During the fourth quarter we achieved our stated goal of reducing sales of certain lower-margin pharmaceutical products, thereby allowing our Medical Group to focus on driving profitable revenue growth in the office-based physician market," said Mr. Bergman.

"Early in 2008 we announced the appointment of Michael Racioppi to Chief Merchandising Officer, a new corporate leadership position with responsibility for optimizing the Company's global gross profit, and named David McKinley as President of Henry Schein's Medical Group," he added. "I am very excited about the future contributions of each of these two executives."

For the quarter International Group sales increased 42.5%, including 30.1% growth in local currencies (5.0% internally generated and 25.1% from acquisitions) and 12.4% related to foreign currency exchange.

"Sales growth in our International Group was driven by strong gains in the United Kingdom, Spain, Italy and the Benelux countries," commented Mr. Bergman. "I am pleased to report that W. & J. Dunlop, a leading United Kingdom animal health products supplier we acquired during the third quarter of 2007, is performing consistent with our expectations."

Technology and Value-Added Services Group sales increased 44.8% during the fourth quarter of 2007, including 44.0% growth in local currencies (15.5% internally generated and 28.5% acquisition growth) and 0.8% growth related to foreign currency exchange.

"Technology and Value-Added Services results reflect continued strong electronic services, software and financial services revenue growth," stated Mr. Bergman. "Revenue includes a full quarter contribution from Software of Excellence, a leading supplier of practice management systems in the United Kingdom, Australia and New Zealand."

Full-Year 2007 Results

For 2007 net sales of \$5.9 billion represent an increase of 17.3% compared with 2006. This increase includes 14.3% local currency growth (7.3% internally generated and 7.0% from acquisitions, net of divestiture) and 3.0% related to foreign currency exchange. Income from continuing operations for 2007 was \$235.0 million or \$2.58 per diluted share, up 28.6% and 27.1%, respectively, compared with 2006.

2008 EPS Guidance

Henry Schein affirms 2008 financial guidance, as follows:

- 2008 diluted EPS is expected to be \$2.93 to \$3.00, representing growth of 14% to 16% compared with 2007.
- o This 2008 diluted EPS guidance includes Henry Schein's expectation that it will distribute 12 million to 15 million doses of influenza vaccine during the year, representing earnings of \$0.13 to \$0.16 per diluted share.
- o 2008 diluted EPS guidance is for current continuing operations including completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any.

Fourth Quarter Conference Call Webcast

The Company will hold a conference call to discuss fourth quarter financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call over the Internet through Henry Schein's Web site at www.henryschein.com. In addition, a replay will be available beginning shortly after the call has ended.

About Henry Schein

Henry Schein, a Fortune 500(R) company and a member of the NASDAQ 100(R) Index, is recognized for its excellent customer service and highly competitive prices. The Company's four business groups - Dental, Medical, International and Technology - serve more than 550,000 customers worldwide, including dental practitioners and laboratories, physician practices and animal health clinics, as well as government and other institutions. The Company operates through a centralized and automated distribution network, which provides customers in more than 200 countries with a comprehensive selection of more than 90,000 national and Henry Schein private-brand products in stock, as well as more than 100,000 additional products available as special-order items.

Henry Schein also offers a wide range of innovative value-added practice solutions for healthcare professionals, such as ArubA(R), the Company's electronic catalog and ordering system. Its leading practice-management software solutions have an installed user base of more than 52,000 practices, including DENTRIX(R), Easy Dental(R), Oasis(R) and EXACT(R) for dental practices, MicroMD(R) for physician practices, and AVImark(R) for animal health clinics.

Headquartered in Melville, N.Y., Henry Schein employs over 12,000 people and has operations or affiliates in 20 countries. The Company's net sales reached a record \$5.9 billion in 2007. For more information, visit the Henry Schein Web site at www.henryschein.com.

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors which, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements, or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: competitive factors; changes in the healthcare industry; changes in regulatory requirements that affect us; risks associated with our international operations; fluctuations in quarterly earnings; our dependence on third parties for the manufacture and supply of our products; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; regulatory and litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; our dependence upon sales personnel and key customers; our dependence on our senior management; possible increases in the cost of shipping our products or other service trouble with our third-party shippers; risks from rapid technological change; risks from potential increases in variable interest rates; possible volatility of the market price of our common stock; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation that affect us. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, forward-looking statements should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

4 - more -

(TABLES TO FOLLOW)

HENRY SCHEIN, INC. CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share data)

	Three Months Ended			Years Ended				
	December 29, 2007		December 30, 2006		December 29, 2007		December 30, 2006	
	(unaudited)	(unaudited)				
Net sales		1,717,470 1,233,339	\$	1,475,064 1,054,931		5,920,190 4,201,906		5,048,191 3,576,234
Gross profit		484,131		420,133		1,718,284		1,471,957
Operating expenses: Selling, general and administrative		359,145		315,594		1,332,025		1,167,822
Operating income						386,259		304, 135
Interest income Interest expense Other, net		3,765 (6,796) 288		4,398 (6,520) (120)		16,531 (25,177) 4,630		16,378 (27,627) 2,045
Income from continuing operations before taxes, minority interest and equity in earnings (losses) of affiliates		122,243 (39,974) (6,438) 614		102,297 (35,870) (3,643) 254		382,243 (129,762) (17,442) (73)		294, 931 (104, 932) (8, 090) 835
Income from continuing operations						234,966		182,744
Discontinued operations: Income (loss) from operations of discontinued components (including write-down of long-lived assets of \$32.7 million in 2007 and a net gain on sale of discontinued operations of \$1.1 million in 2007 and a \$32.3 million loss on sale of discontinued operation in 2006)		2,882		(7)		(31,420)		(31,608)
Income tax benefit (expense)		(1,058)		(34)		11,627		12,623
Income (loss) from discontinued operations		1,824		(41)		(19,793)		(18,985)
Net income		78,269 =====	\$ ==:	62,997 ======	\$ ===	215,173 ======	\$ ==:	163,759 ======
Earnings from continuing operations per share:	Φ.	0.00	Φ.	0 71	Φ.	2.65	Φ.	2.00
Basic Diluted	==	0.86		0.71		2.65		2.08
Diffuted		0.83 ======	\$ ==:	0.70 =====	\$ ===	2.58	\$ ==:	2.03 ======
Income (loss) from discontinued operations per share: Basic	\$	0.02	\$	0.00	\$	(0.22)	\$	(0.22)
Diluted	\$	0.02	\$	0.00	\$	(0.22)	\$	(0.21)
Earnings per share:								
Basic		0.88 ========		0.71 ======		2.43		1.86 ======
Diluted	\$ ==:	0.85 =====	\$ ==:	0.70 =====	\$ ===	2.36	\$ ==:	1.82
Weighted-average common shares outstanding: Basic		89,082		88,580		88,559		87,952
Diluted	==	92,031	==:	90,488	===	91,163	==:	89,820
D220000	==	========	==:	=======	===	========	==:	========

Note: The above prior period amounts have been restated to reflect the effects of our discontinued operations.

HENRY SCHEIN, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data)

	December 29, 2007	December 30, 2006
ASSETS Current assets:		
Cash and cash equivalents Available-for-sale securities Accounts receivable, net of reserves of \$41,315 and \$40,536 Inventories, net Deferred income taxes Prepaid expenses and other	\$ 247,590 997 708,307 666,786 32,827 192,292	\$ 248,647 47,999 610,020 584,103 28,240 125,839
Total current assets Property and equipment, net Goodwill Other intangibles, net Investments and other	1,848,799 247,671 917,194 192,420 107,900	1,644,848 225,038 773,801 161,542 75,917
Total assets	\$ 3,313,984 =========	\$ 2,881,146 =========
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Bank credit lines Current maturities of long-term debt Accrued expenses: Payroll and related Taxes Other Total current liabilities Long-term debt Deferred income taxes Other liabilities Minority interest	\$ 474,009 8,977 24,319 136,291 73,278 223,765 940,639 423,274 80,260 53,906	\$ 414,062 2,528 41,036 110,401 59,007 183,054
Stockholders' equity: Preferred stock, \$.01 par value, 1,000,000 shares authorized, none outstanding	896 673,763 1,005,055 100,268	885 614,551 808,164 47,363
Total liabilities and stockholders' equity	\$ 3,313,984	\$ 2,881,146
	=========	========

HENRY SCHEIN, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)

Three Months Ended

		ember 29, 2007		ember 30, 2006
		naudited)		audited)
Cash flows from operating activities:				
Net income Adjustments to reconcile net income to net cash provided by operating activities: Loss (gain) on sale of discontinued operation, net of tax Depreciation and amortization Stock-based compensation expense	\$	78,269 (1,602) 20,915 5,833	\$	62,997 18,039 5,531
Impairment from write down of long-lived assets of discontinued operations		322 9,326 (614)		529 3,959 (254)
Minority interest in net income of subsidiaries		6,438 (3,642) 60,557		3,643 483 (287)
Inventories		15,995 (48,353) (23,158)		(5,991) 11,048 70,994
Net cash provided by operating activities		120,286		170,691
Cash flows from investing activities: Purchases of fixed assets		(23,798)		(17,073)
net of cash acquired		(81,884)		(13,748)
Cash received from business divestitures		10,766 27,750		(57,999) 8,000
Proceeds from maturities of available-for-sale securities Net payments for foreign exchange forward contract settlements Other		(15, 261) 408		2,000 (5,633) 3,113
Net cash used in investing activities		(82,019)		(81,340)
		(02,019)		
Cash flows from financing activities: Proceeds from issuance of long-term debt Proceeds from (repayments of) bank borrowings Principal payments for long-term debt Proceeds from issuance of stock upon exercise of stock options Payments for repurchases of common stock Excess tax benefits related to stock-based compensation Other		5,766 (5,374) 2,740 - 1,071 (471)		1,201 (113) (3,860) 2,722 (14,563) 1,700
Net cash provided by (used in) financing activities		3,732		(12,909)
Net change in cash and cash equivalents		41,999 (1,867) 207,458		76,442 (3,865) 176,070
Cash and cash equivalents, end of period	\$	247,590 ======	\$	248,647 ======
		Years	Ended	
	Dec	ember 29, 2007	Dec	
Cash flows from operating activities:				
Net income	\$	215,173	\$	163,759
Loss (gain) on sale of discontinued operation, net of tax Depreciation and amortization		(673) 73,936 22,553		19,363 64,930 19,464
discontinued operations		32,667 1,384 (7,404)		2,872 1,297

Stock issued to 40(k) plan 4,104 3,5665 Undistributed (earnings) losses of affiliates 73 (835) Minority interest in net income of subsidiaries 17,442 8,090 Other (6,512) (2,066) Changes in operating assets and liabilities, net of acquisitions: (21,964) (9,705) Inventories (15,946) (41,958) Other current assets (58,194) 18,424 Accounts payable and accrued expenses 13,572 (11,883) Net cash provided by operating activities 279,211 235,317 Cash flows from investing activities: (56,821) (67,600) Purchases of fixed assets (56,821) (67,600) Payments for equity investment and business acquisitions, net of cash acquired (206,182) (199,880) Cash received from business divestitures 15,827 36,527 Purchases of available-for-sale securities (15,906) (222,036) Proceeds from maturities of available-for-sale securities (12,066) (222,036) Proceeds from maturities of available-for-sale securities (3,2241) (22,256)			
Minority interest in net income of subsidiaries 17,442 8,090 Other (6,512) (2,066) Changes in operating assets and liabilities, net of acquisitions: (21,964) (9,765) Inventories (15,946) (41,958) Other current assets (58,194) 18,424 Accounts payable and accrued expenses 13,572 (11,683) Net cash provided by operating activities: 270,211 235,317 Cash flows from investing activities: (56,821) (67,000) Purchases of fixed assets (56,821) (67,000) Payments for equity investment and business acquisitions, net of cash acquired (206,182) (199,880) Cash received from business divestitures (15,827) 36,527 Purchases of available-for-sale securities (115,066) (222,036) Proceeds from maturities of available-for-sale securities (30,065) 294,767 Proceeds from maturities of available-for-sale securities (32,241) (22,528) Net cash used in investing activities (32,241) (22,528) Other (30,065) (34,467) (160,361)		4,104	3,565
Other (6,512) (2,066) Changes in operating assets and liabilities, net of acquisitions: (21,964) (9,765) Inventories (15,946) (41,958) Other current assets (58,194) 18,424 Accounts payable and accrued expenses 13,572 (11,883) Net cash provided by operating activities 270,211 225,317 Cash flows from investing activities: (56,821) (67,000) Purchases of fixed assets (56,821) (67,000) Payments for equity investment and business acquisitions, (206,182) (199,880) Cash received from business divestitures 15,827 36,527 Purchases of fixed assets (15,666) (222,038) Cash received from business divestitures 15,827 36,527 Purchases of available-for-sale securities (15,666) (222,038) Proceeds from maturities of available-for-sale securities 163,065 294,767 Proceeds from maturities of available-for-sale securities (32,241) (22,528) Other (22,528) (34,677) (180,632) Net cash used in invest	Undistributed (earnings) losses of affiliates	73	(835)
Changes in operating assets and liabilities, net of acquisitions: (21,964) (9,765) Accounts receivable (15,946) (41,958) Other current assets (58,194) 18,424 Accounts payable and accrued expenses 13,572 (11,883) Net cash provided by operating activities 270,211 235,317 Cash flows from investing activities: (56,821) (67,000) Purchases of fixed assets (56,821) (67,000) Payments for equity Investment and business acquisitions, net of cash acquired (206,182) (199,880) Cash received from business divestitures 15,827 36,527 Purchases of available-for-sale securities 15,827 36,527 Purchases of available-for-sale securities 163,065 294,767 Proceeds from sales of available-for-sale securities -3,280 294,767 Proceeds from sales of available-for-sale securities -3,280 36,065 294,767 Proceeds from sales of available-for-sale securities -3,280 36,065 294,767 Proceeds from sales of available-for-sale securities -1,320 36,065 294,767	Minority interest in net income of subsidiaries	17,442	8,090
Accounts receivable	Other	(6,512)	(2,066)
Inventories	Changes in operating assets and liabilities, net of acquisitions:		
Other current assets (58,194) 18,424' Accounts payable and acrued expenses 13,572 (11,883) Net cash provided by operating activities 270,211 235,317 Cash flows from investing activities: 270,211 235,317 Cash flows from investing activities: (56,821) (67,000) Payments for equity investment and business acquisitions, net of cash acquired (206,182) (199,880) Cash received from business divestitures 15,827 36,527 Purchases of available-for-sale securities (15,066) (222,036) Proceeds from sales of available-for-sale securities 163,065 294,767 Proceeds from maturities of available-for-sale securities 1,227 3,280 Net payments for foreign exchange forward contract settlements (32,241) (22,528) Other (19,629) (3,491) Net cash used in investing activities 483 1,201 Proceeds from issuance of long-term debt 483 1,201 Proceeds from issuance of long-term debt (47,993) (34,537) Proceeds from issuance of stock upon exercise of stock options 35,459	Accounts receivable	(21,964)	(9,705)
Accounts payable and accrued expenses 13,572 (11,883) Net cash provided by operating activities 270,211 235,317 Cash flows from investing activities:	Inventories	(15,946)	(41,958)
Net cash provided by operating activities 270,211 235,317 Cash flows from investing activities (56,821) (67,000) Payments for equity investment and business acquisitions, net of cash acquired (296,182) (199,880) Cash received from business divestitures 15,827 36,527 Purchases of available-for-sale securities (115,066) (222,036) Proceeds from sales of available-for-sale securities 163,065 294,767 Proceeds from maturities of available-for-sale securities 163,065 294,767 Proceeds from maturities of available-for-sale securities 3,280 Net payments for foreign exchange forward contract settlements (32,241) (22,528) Other	Other current assets	(58, 194)	18,424
Net cash provided by operating activities: 270,211 235,317 Cash flows from investing activities: (56,821) (67,000) Payments for equity investment and business acquisitions, net of cash acquired (206,182) (199,880) Cash received from business divestitures 15,827 36,527 Purchases of available-for-sale securities (115,066) (222,036) Proceeds from sales of available-for-sale securities 163,065 294,767 Proceeds from maturities of available-for-sale securities (32,241) (22,528) Net payments for foreign exchange forward contract settlements (32,241) (22,528) Other (10,629) (3,491) Net cash used in investing activities (242,047) (180,361) Cash flows from financing activities: 242,047) (180,361) Proceeds from issuance of long-term debt 483 1,212 Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock (30,689) (40,263) Payments for repurchases of common stock (30,689) (40,263) Excess tax benefits related to	Accounts payable and accrued expenses	13,572	
Cash flows from investing activities: (56,821) (67,000) Payments for equity investment and business acquisitions, net of cash acquired (206,182) (199,880) Cash received from business divestitures 15,827 36,527 Purchases of available-for-sale securities (115,066) (222,036) Proceeds from sales of available-for-sale securities 163,065 294,767 Proceeds from maturities of available-for-sale securities - 3,280 Net payments for foreign exchange forward contract settlements (32,241) (22,528) Other (10,629) (3,491) Net cash used in investing activities (242,047) (180,361) Cash flows from financing activities: (242,047) (180,361) Proceeds from issuance of long-term debt 483 1,201 Proceeds from (repayments of) bank borrowings 1,212 184 Principal payments for long-term debt (47,903) (34,537) Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock (30,689) (40,233) Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 <t< td=""><td></td><td></td><td></td></t<>			
Cash flows from investing activities: (56,821) (67,000) Payments for equity investment and business acquisitions, net of cash acquired (206,182) (199,886) Cash received from business divestitures (15,966) (222,036) Proceeds from sales of available-for-sale securities (115,066) (222,036) Proceeds from maturities of available-for-sale securities 163,065 294,767 Proceeds from maturities of available-for-sale securities - 3,280 Net payments for foreign exchange forward contract settlements (32,241) (22,528) Other (10,629) (3,491) Net cash used in investing activities (242,047) (180,361) Cash flows from financing activities 483 1,201 Proceeds from issuance of long-term debt 483 1,201 Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock (39,689) (40,263) Excess tax benefits related to stock-based compensation 12,668 14,850 Other (2,356) 31,682 Net change in cash and cash equivalents (2,956) 33,682 Cash and cash equival	Net cash provided by operating activities		
Purchases of fixed assets			
Payments for equity investment and business acquisitions, net of cash acquired (206,182) (199,880) Cash received from business divestitures 15,827 36,527 Purchases of available-for-sale securities (115,066) (222,036) Proceeds from maturities of available-for-sale securities 163,065 294,767 Proceeds from maturities of available-for-sale securities - 3,280 Net payments for foreign exchange forward contract settlements (32,241) (22,528) Other (10,629) (3,491) Net cash used in investing activities (242,047) (180,361) Cash flows from financing activities: *** *** Proceeds from issuance of long-term debt 483 1,201 Proceeds from issuance of box box box box options 1,212 184 Principal payments for long-term debt (47,903) (34,537) Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock (30,689) (40,235) Excess tax benefits related to stock-based compensation 12,668 14,850 Other (2,350)	Cash flows from investing activities:		
net of cash acquired (296, 182) (199,880) Cash received from business divestitures 15,827 36,527 Purchases of available-for-sale securities (115,066) (222,036) Proceeds from sales of available-for-sale securities 163,065 294,767 Proceeds from maturities of available-for-sale securities - 3,280 Net payments for foreign exchange forward contract settlements (32,241) (22,528) Other (10,629) (3,491) Net cash used in investing activities (242,047) (180,361) Proceeds from issuance of long-term debt 483 1,201 Proceeds from (repayments of) bank borrowings 1,212 184 Principal payments for long-term debt (47,993) (34,537) Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock (30,689) (40,263) Excess tax benefits related to stock-based compensation 12,668 14,850 Other (2,350) 1,669 Net change in cash and cash equivalents (2,956) 33,682 Ef		(56,821)	(67,000)
Cash received from business divestitures 15,827 36,527 Purchases of available-for-sale securities (115,066) (222,036) Proceeds from sales of available-for-sale securities 163,065 294,767 Proceeds from maturities of available-for-sale securities - 3,280 Net payments for foreign exchange forward contract settlements (32,241) (22,528) Other (10,629) (3,491) Net cash used in investing activities (242,047) (180,361) Cash flows from financing activities: - 483 1,201 Proceeds from issuance of long-term debt 483 1,201 Proceeds from (repayments of) bank borrowings 1,212 184 Principal payments for long-term debt (47,903) (34,537) Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock (30,689) (40,263) Excess tax benefits related to stock-based compensation 12,668 14,850 Other (2,350) 1,669 Net change in cash and cash equivalents (2,956) 33,682 Effect of exchange rate changes on cash and cash equivalents	Payments for equity investment and business acquisitions,		
Purchases of available-for-sale securities (115,066) (222,036) Proceeds from sales of available-for-sale securities 163,065 294,767 Proceeds from maturities of available-for-sale securities - 3,280 Net payments for foreign exchange forward contract settlements (32,241) (22,528) Other (10,629) (3,491) Net cash used in investing activities (242,047) (180,361) Cash flows from financing activities: - - Proceeds from issuance of long-term debt 483 1,201 Proceeds from (repayments of) bank borrowings 1,212 184 Principal payments for long-term debt (47,903) (34,537) Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock (30,689) (40,263) Excess tax benefits related to stock-based compensation 12,668 14,850 Other (2,350) 1,669 Net cash provided by (used in) financing activities (31,120) (21,274) Net change in cash and cash equivalents 1,899 4,282		(206, 182)	(199,880)
Proceeds from sales of available-for-sale securities 163,065 294,767 Proceeds from maturities of available-for-sale securities - 3,280 Net payments for foreign exchange forward contract settlements (32,241) (22,528) Other (10,629) (3,491) Net cash used in investing activities (242,047) (180,361) Cash flows from financing activities: (242,047) (180,361) Proceeds from issuance of long-term debt 483 1,201 Principal payments of) bank borrowings 1,212 184 Principal payments for long-term debt (47,993) (34,537) Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock (30,689) (40,263) Excess tax benefits related to stock-based compensation 12,668 14,850 Other (2,356) 33,682 Net cash provided by (used in) financing activities (31,120) (21,274) Net change in cash and cash equivalents 1,899 4,282 Cash and cash equivalents, beginning of period 248,647 210,683	Cash received from business divestitures	15,827	36,527
Proceeds from maturities of available-for-sale securities - 3,280 Net payments for foreign exchange forward contract settlements (32,241) (22,528) Other (10,629) (3,491) Net cash used in investing activities (242,047) (180,361) Cash flows from financing activities: - 483 1,201 Proceeds from issuance of long-term debt 483 1,212 Principal payments for long-term debt (47,903) (34,537) Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock (30,689) (40,263) Excess tax benefits related to stock-based compensation 12,668 14,850 Other (2,350) 1,669 Net cash provided by (used in) financing activities (31,120) (21,274) Net change in cash and cash equivalents (2,956) 33,682 Effect of exchange rate changes on cash and cash equivalents 1,899 4,282 Cash and cash equivalents, beginning of period \$247,590 \$248,647 210,683	Purchases of available-for-sale securities	(115,066)	(222,036)
Net payments for foreign exchange forward contract settlements (32,241) (22,528) Other (10,629) (3,491) Net cash used in investing activities (242,047) (180,361) Cash flows from financing activities: Proceeds from issuance of long-term debt 483 1,201 Proceeds from (repayments of) bank borrowings 1,212 184 Principal payments for long-term debt (47,903) (34,537) Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock (30,689) (40,263) Excess tax benefits related to stock-based compensation 12,668 14,850 Other (2,350) 1,669 Net cash provided by (used in) financing activities (31,120) (21,274) Net change in cash and cash equivalents (2,956) 33,682 Effect of exchange rate changes on cash and cash equivalents 1,899 4,282 Cash and cash equivalents, beginning of period \$248,647 210,683	Proceeds from sales of available-for-sale securities	163,065	294,767
Other (10,629) (3,491) Net cash used in investing activities (242,047) (180,361) Cash flows from financing activities:	Proceeds from maturities of available-for-sale securities		3,280
Net cash used in investing activities . (242,047) (180,361) Cash flows from financing activities: Proceeds from issuance of long-term debt . 483 1,201 Proceeds from (repayments of) bank borrowings . 1,212 184 Principal payments for long-term debt . (47,903) (34,537) Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock . (30,689) (40,263) Excess tax benefits related to stock-based compensation 12,668 14,850 0ther . (2,350) 1,669 Net cash provided by (used in) financing activities . (31,120) (21,274) Net change in cash and cash equivalents . (2,956) 33,682 Effect of exchange rate changes on cash and cash equivalents . 1,899 4,282 Cash and cash equivalents, beginning of period . \$247,590 \$248,647	Net payments for foreign exchange forward contract settlements	(32,241)	(22,528)
Net cash used in investing activities . (242,047) (180,361) Cash flows from financing activities: Proceeds from issuance of long-term debt . 483 1,201 Proceeds from (repayments of) bank borrowings . 1,212 184 Principal payments for long-term debt . (47,903) (34,537) Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock . (30,689) (40,263) Excess tax benefits related to stock-based compensation . 12,668 14,850 Other (2,350) 1,669 Net cash provided by (used in) financing activities . (31,120) (21,274) Net change in cash and cash equivalents . (2,956) 33,682 Effect of exchange rate changes on cash and cash equivalents . 1,899 4,282 Cash and cash equivalents, beginning of period . \$247,590 \$248,647	Other	(10,629)	(3,491)
Cash flows from financing activities: Proceeds from issuance of long-term debt			
Proceeds from issuance of long-term debt	Net cash used in investing activities	(242,047)	(180,361)
Proceeds from issuance of long-term debt			
Proceeds from (repayments of) bank borrowings 1,212 184 Principal payments for long-term debt (47,903) (34,537) Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock (30,689) (40,263) Excess tax benefits related to stock-based compensation 12,668 14,850 (2,350) 1,669 Net cash provided by (used in) financing activities (31,120) (21,274) Net change in cash and cash equivalents (2,956) 33,682 Effect of exchange rate changes on cash and cash equivalents 1,899 4,282 Cash and cash equivalents, beginning of period \$248,647 210,683 Cash and cash equivalents, end of period \$247,590 \$248,647			
Principal payments for long-term debt			,
Proceeds from issuance of stock upon exercise of stock options 35,459 35,622 Payments for repurchases of common stock (30,689) (40,263) Excess tax benefits related to stock-based compensation 12,668 14,850 Other (2,350) 1,669 Net cash provided by (used in) financing activities (31,120) (21,274) Net change in cash and cash equivalents (2,956) 33,682 Effect of exchange rate changes on cash and cash equivalents 1,899 4,282 Cash and cash equivalents, beginning of period 248,647 210,683 Cash and cash equivalents, end of period \$ 247,590 \$ 248,647		,	
Payments for repurchases of common stock (30,689) (40,263) Excess tax benefits related to stock-based compensation 12,668 14,850 Other (2,350) 1,669 Net cash provided by (used in) financing activities (31,120) (21,274) Net change in cash and cash equivalents (2,956) 33,682 Effect of exchange rate changes on cash and cash equivalents 1,899 4,282 Cash and cash equivalents, beginning of period 248,647 210,683 Cash and cash equivalents, end of period \$ 247,590 \$ 248,647		` ' '	` ' '
Excess tax benefits related to stock-based compensation 12,668 14,850 Other (2,350) 1,669 Net cash provided by (used in) financing activities (31,120) (21,274) Net change in cash and cash equivalents (2,956) 33,682 Effect of exchange rate changes on cash and cash equivalents 1,899 4,282 Cash and cash equivalents, beginning of period 248,647 210,683 Cash and cash equivalents, end of period \$ 247,590 \$ 248,647			
Other			
Net cash provided by (used in) financing activities			
Net cash provided by (used in) financing activities	Other		
Net change in cash and cash equivalents			
Net change in cash and cash equivalents	Net cash provided by (used in) financing activities	(31,120)	(21,274)
Effect of exchange rate changes on cash and cash equivalents	Not change in each and each equivalents		
Cash and cash equivalents, beginning of period 248,647 210,683 Cash and cash equivalents, end of period \$ 247,590 \$ 248,647			
Cash and cash equivalents, end of period		,	,
Cash and cash equivalents, end of period	cash and cash equivarents, beginning of period		
	Cash and cash equivalents end of period		
	Sault and Sault Squittatenes, and of period		

Henry Schein, Inc. 2007 Fourth Quarter Sales Growth Rate Summary (unaudited)

Q4 2007 over Q4 2006

	Consolidated	Dental	Medical	International	Technology
Internal Sales Growth	3.8%	9.4%	-6.0%	5.0%	15.5%
Acquisitions	8.5%	1.8%	0.5%	25.1%	28.5%
Local Currency Sales Growth	12.3%	11.2%	-5.5%	30.1%	44.0%
Foreign Currency Exchange	4.1%	1.6%		12.4%	0.8%

Q4 YTD 2007 over Q4 YTD 2006

	Consolidated	Dental	Medical	International	Technology
Internal Sales Growth	7.3%	10.0%	5.5%	4.3%	18.4%
Acquisitions, net of divestiture	7.0%	4.6%	4.8%	12.3%	15.6%
Local Currency Sales Growth	14.3%	14.6%	10.3%	16.6%	34.0%
Foreign Currency Exchange	3.0%	0.6%		9.6%	0.3%
Total Sales Growth	17.3%	15.2% ======	10.3%	26.2%	34.3%

CONTACTS: Steven Paladino

Total Sales Growth

Executive Vice President and Chief Financial Officer

steven.paladino@henryschein.com

(631) 843-5500

Investors: Neal Goldner Vice President, Investor Relations neal.goldner@henryschein.com

(631) 845-2820

Media: Susan Vassallo

Vice President, Corporate Communications susan.vassallo@henryschein.com

(631) 843-5562

8 ###